The Europe Testosterone Replacement Therapy Market would witness market growth of 3.7% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Testosterone Replacement Therapy Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $163.9 million by 2031. The UK market is exhibiting a CAGR of 3.2% during (2024 - 2031). Additionally, The France market would experience a CAGR of 4.5% during (2024 - 2031).
Andropause, often referred to as male menopause, is a natural age-related decline in testosterone levels that occurs in aging men. While not all men experience significant symptoms, some may develop symptoms similar to those seen in hypogonadism, such as fatigue, reduced libido, mood changes, and decreased muscle mass. TRT can help manage these symptoms and improve the overall quality of life in aging men experiencing andropause.
In addition, testosterone plays a crucial role in erectile function by stimulating nitric oxide production, which relaxes blood vessels in the penis, allowing for increased blood flow and erection. Low testosterone levels can contribute to erectile dysfunction (ED), and TRT may be prescribed as part of a comprehensive treatment plan for men with ED associated with hypogonadism.
As obesity rates rise in the UK, there may be a corresponding increase in the prevalence of hypogonadism or testosterone deficiency among obese individuals. This higher prevalence of hypogonadism could drive greater demand for TRT to address hormone imbalances and associated symptoms. Therefore, the market is growing as a result of the high rates of obesity and the growth of the pharmaceutical business.
Based on End User, the market is segmented into Clinics, and Hospital. Based on Product Type, the market is segmented into Injectables, Topical, and Others. Based on Active ingredients, the market is segmented into Testosterone Cypionate, Testosterone Undecanoate, Testosterone Enanthate, Testosterone, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Testosterone Replacement Therapy Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $163.9 million by 2031. The UK market is exhibiting a CAGR of 3.2% during (2024 - 2031). Additionally, The France market would experience a CAGR of 4.5% during (2024 - 2031).
Andropause, often referred to as male menopause, is a natural age-related decline in testosterone levels that occurs in aging men. While not all men experience significant symptoms, some may develop symptoms similar to those seen in hypogonadism, such as fatigue, reduced libido, mood changes, and decreased muscle mass. TRT can help manage these symptoms and improve the overall quality of life in aging men experiencing andropause.
In addition, testosterone plays a crucial role in erectile function by stimulating nitric oxide production, which relaxes blood vessels in the penis, allowing for increased blood flow and erection. Low testosterone levels can contribute to erectile dysfunction (ED), and TRT may be prescribed as part of a comprehensive treatment plan for men with ED associated with hypogonadism.
As obesity rates rise in the UK, there may be a corresponding increase in the prevalence of hypogonadism or testosterone deficiency among obese individuals. This higher prevalence of hypogonadism could drive greater demand for TRT to address hormone imbalances and associated symptoms. Therefore, the market is growing as a result of the high rates of obesity and the growth of the pharmaceutical business.
Based on End User, the market is segmented into Clinics, and Hospital. Based on Product Type, the market is segmented into Injectables, Topical, and Others. Based on Active ingredients, the market is segmented into Testosterone Cypionate, Testosterone Undecanoate, Testosterone Enanthate, Testosterone, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Endo International PLC
- AbbVie, Inc.
- Pfizer, Inc.
- Eli Lilly And Company
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Ferring Holdings SA
- Marius Pharmaceuticals LLC
- Besins Healthcare Monaco S.A.M.
- Acrux Limited
Market Report Segmentation
By End User- Clinics
- Hospital
- Injectables
- Topical
- Others
- Testosterone Cypionate
- Testosterone Undecanoate
- Testosterone Enanthate
- Testosterone
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Testosterone Replacement Therapy Market by End User
Chapter 5. Europe Testosterone Replacement Therapy Market by Product Type
Chapter 6. Europe Testosterone Replacement Therapy Market by Active ingredients
Chapter 7. Europe Testosterone Replacement Therapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Endo International PLC
- AbbVie, Inc.
- Pfizer, Inc.
- Eli Lilly And Company
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Ferring Holdings SA
- Marius Pharmaceuticals LLC
- Besins Healthcare Monaco S.A.M.
- Acrux Limited
Methodology
LOADING...
